Form 8-K · Current report
Illumina, Inc. 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0001110803
- Accession no.
- 0001110803-26-000202
Summary
Illumina reported third-quarter fiscal 2026 revenue of $1.13 billion, up 4.2% year over year, and raised its full-year revenue and earnings guidance, citing clinical demand and NovaSeq X placements, according to CEO Jacob Thaysen. The quarter's results exclude expected refunds under IEEPA tariffs, which added a $79 million benefit to cost of revenue and reduced revenue by $37 million for refunds to be credited to customers.
Key points
- Q3 2026 revenue was $1.13 billion, up 4.2% from Q3 2025; GAAP diluted EPS was $1.43 and non-GAAP diluted EPS excluding tariff refunds was $1.44.
- Illumina raised fiscal 2026 guidance to total revenue of $4.64–$4.66 billion and non-GAAP diluted EPS of $5.40–$5.45, from prior guidance of $4.60–$4.64 billion and $5.30–$5.40.
- Q3 2026 figures exclude IEEPA tariff refunds, including a $79 million benefit reducing cost of revenue and a $37 million revenue reduction for refunds expected to be credited to customers.
- Cash flow from operations was $419 million and free cash flow $378 million for the quarter, with $1.34 billion in cash, cash equivalents and short-term investments at quarter end.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition Item 9.01 Financial Statements and Exhibits SIGNATURES Exhibit Index Table of Contents Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the third quarter ended September 27, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.